Head and Neck Neuroendocrine Carcinoma — Trials

Head and Neck Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 27
Recruiting: 10
Ph III recruiting: 1
Growth YoY: —
Industry share: 30%
Top sponsor: Eli Lilly and Company
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04161391	Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations	terminated	Phase 1 / Phase 2	41	Turning Point Therapeutics, Inc.INDUSTRY	2	Jun 13, 2024	clinicaltrials
NCT03630120	Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer	terminated	Phase 2	6	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Jul 14, 2021